ANI Pharmaceuticals beats Q2 revenue, EPS beats estimates and raises FY forecast

ANI Pharmaceuticals

08/08/2025 11:59

Overview

ANI Pharmaceuticals Q2 net revenues rise 53.1% yr/yr to $211.4 mln

Adjusted EPS for Q2 beats consensus, reaching $1.80, per LSEG data

Company raises 2025 guidance, expecting higher net revenues and EPS

Outlook

Company expects 2025 net revenues of $818 mln to $843 mln

ANI Pharmaceuticals sees 2025 adjusted EBITDA of $213 mln to $223 mln

Company anticipates Rare Disease revenues to be 57% of total in H2 2025

ANI forecasts 2025 non-GAAP EPS of $6.98 to $7.35

Result Drivers

RARE DISEASE GROWTH - Cortrophin Gel net revenues increased 66% yr/yr, driven by higher prescription demand and new patient starts

GENERIC LAUNCHES - Generics revenues rose 22.1% yr/yr, fueled by new product launches and operational excellence

OPHTHALMOLOGY EXPANSION - Enhanced sales team and marketing efforts boosted ophthalmology segment, contributing to revenue growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$103.96 mln
$190.30 mln (8 Analysts)
Q2 Adjusted EPS
Beat
$1.8
$1.42 (8 Analysts)
Q2 Net Income
$8.10 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for ANI Pharmaceuticals Inc is $84.00, about 17.8% above its August 7 closing price of $69.01

The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 11 three months ago

Press Release: ID:nGNXnQHfm

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)